Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot PharmaphorumA unanimous endorsement from FDA advisors brings Moderna's RNA-based seasonal influenza vaccine a step closer to US approval.Infectious DiseaseRead full story pharminent June 19, 2026 (Last updated: June 22, 2026) Pharmaphorum A unanimous endorsement from FDA advisors brings Moderna’s RNA-based seasonal influenza vaccine a step closer to US approval. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’Next: Biogen to acquire RayThera for up to $1bn Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
